CAI · ISSUER CIK 2019410
Caris Life Sciences, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 11 Caris Life Sciences, Inc. insiders reported $0.00 of open-market purchases and $27.2M of sales on SEC Form 4.
↗11 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$27.2MInsider selling
−$27.2MNet open-market
Sep 23, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 202617:06 | Sep 22, 2026 | CAI | See Remarks | S · Sell | $31.82 | −7,500 | 174,855 | -4% | −$239K | ||
| Sep 17, 202618:08 | Sep 17, 2026 | CAI | See Remarks, Director | S · Sell | $30.33 | −400,000 | 230,303 | -63% | −$12.1M | ||
| Sep 17, 202618:08 | Sep 17, 2026 | CAI | See Remarks, Director | M · Exercise | $2.44 | +400,000 | 630,303 | +174% | $976K | ||
| Sep 4, 202616:59 | Sep 4, 2026from Sep 3, 2026 | CAI | President | S · Sell | $24.84 | −597,212 | 1,182,871 | -34% | −$14.8M | ||
| Sep 4, 202616:59 | Sep 4, 2026from Sep 3, 2026 | CAI | President | M · Exercise | $2.44 | +1,250,000 | 1,302,083 | +2400% | $3.0M | ||
| Aug 14, 202617:44 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 29,321 | +82% | — | ||
| Aug 14, 202617:43 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 133,060 | +11% | — | ||
| Aug 14, 202617:42 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 31,813 | +71% | — | ||
| Aug 14, 202617:41 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 29,321 | +82% | — | ||
| Aug 14, 202617:41 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 31,813 | +71% | — | ||
| Aug 14, 202617:40 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 62,863 | +27% | — | ||
| Aug 14, 202617:39 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 343,897 | +4% | — | ||
| Aug 14, 202617:38 | Aug 14, 2026 | CAI | Director | A · Grant | — | +13,192 | 131,813 | +11% | — |